Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Gross Margin (2023 - 2025)

Historic Gross Margin for Mirum Pharmaceuticals (MIRM) over the last 3 years, with Q3 2025 value amounting to 80.8%.

  • Mirum Pharmaceuticals' Gross Margin rose 38200.0% to 80.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.92%, marking a year-over-year increase of 72400.0%. This contributed to the annual value of 75.77% for FY2024, which is 10000.0% up from last year.
  • Mirum Pharmaceuticals' Gross Margin amounted to 80.8% in Q3 2025, which was up 38200.0% from 81.67% recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Gross Margin high stood at 84.24% for Q1 2023, and its period low was 64.03% during Q4 2023.
  • Its 3-year average for Gross Margin is 77.53%, with a median of 78.57% in 2023.
  • The largest annual percentage gain for Mirum Pharmaceuticals' Gross Margin in the last 5 years was 130600bps (2024), contrasted with its biggest fall of -100000bps (2024).
  • Mirum Pharmaceuticals' Gross Margin (Quarter) stood at 64.03% in 2023, then grew by 20bps to 77.09% in 2024, then grew by 5bps to 80.8% in 2025.
  • Its Gross Margin stands at 80.8% for Q3 2025, versus 81.67% for Q2 2025 and 79.37% for Q1 2025.